Lapatinib
Sign in to save this workspacePrimary targets: EGFR, ERBB2_HER2 · FDA status: FDA Approved
Selectivity scorecard
KISS
99.25
Gini
0.616
CATDS
0.038
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Lapatinib. Strongest target: EGFR at 99.2% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | EGFR | 99.2% | 0.8% |
| 2 | ERBB4_HER4 | 97.8% | 2.2% |
| 3 | ERBB2_HER2 | 95.8% | 4.2% |
| 4 | RIPK3 | 52.5% | 47.5% |
| 5 | SLK_STK2 | 51.5% | 48.5% |
| 6 | ARAF | 47.3% | 52.7% |
| 7 | CAMKK2 | 37.0% | 63.0% |
| 8 | PKMYT1 | 31.1% | 68.9% |
| 9 | BRK | 30.3% | 69.7% |
| 10 | RAF1 | 29.6% | 70.4% |
| 11 | RIPK4 | 28.9% | 71.1% |
| 12 | ERN1_IRE1 | 28.5% | 71.5% |
| 13 | TRPM7_CHAK1 | 25.7% | 74.3% |
| 14 | TLK1 | 25.0% | 75.0% |
| 15 | PKCNU_PRKD3 | 21.9% | 78.1% |
| 16 | PDK2_PDHK2 | 21.4% | 78.6% |
| 17 | HASPIN | 20.8% | 79.2% |
| 18 | NEK8 | 20.0% | 80.0% |
| 19 | IKKA_CHUK | 20.0% | 80.0% |
| 20 | TTBK2 | 19.9% | 80.1% |
Selectivity landscape
Where Lapatinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Lapatinib.
Annotations
Sign in to read and post annotations.
Loading…